Who
William E. Duke
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Invivyd; Chief Financial Officer, Apexigen; Chief Financial Officer, Kaleido Biosciences; Chief Financial Officer, Pulmatrix.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $220K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 24 Jun 2015
- Last trade
- 18 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $16K18,425 at $0.8429 | filing |
| 18 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $15K18,425 at $0.84 | filing |
| 17 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $16K22,355 at $0.722 | filing |
| 17 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $16K22,355 at $0.72 | filing |
| 15 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Code M | —102,000 | filing |
| 15 Aug 2026filed 18 Aug 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code M | —102,000 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code M | —102,000 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Code M | —102,000 | filing |
| 18 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $33K20,964 at $1.58 | filing |
| 18 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $33K20,964 at $1.58 | filing |
| 17 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $30K19,663 at $1.54 | filing |
| 17 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $30K19,663 at $1.54 | filing |
| 15 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Code M | —99,000 | filing |
| 15 Feb 2026filed 18 Feb 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code M | —99,000 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code M | —99,000 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | IVVD InvivydBiotechnology | SEC FORM 4 Code M | —99,000 | filing |
| 29 Jan 2026filed 30 Jan 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —625,000 at $0.00 | filing |
| 29 Jan 2026filed 30 Jan 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —625,000 at $0.00 | filing |
| 19 Aug 2025filed 19 Aug 2025 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $17K29,643 at $0.57 | filing |
| 18 Aug 2025filed 19 Aug 2025 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $13K20,013 at $0.65 | filing |
News
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026IVVD · manilatimes.net · 21 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastIVVD · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name William E. Duke; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.